- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nektar Therapeutics (NKTR)
Assess today's live Nektar Therapeutics (NKTR) share price, performance and insights using our live NASDAQ: NKTR stock exchange data.
Analyse the historical data and Nektar Therapeutics share price performance charts on this page. Our technical summary section provides analysis on Nektar share price buy/sell indicators using real-time data (or discuss the Nektar (NKTR) stock price today with other investors in the Nektar NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ NKTR share price (ISIN: US6402683063) to enhance your trading decisions with our free investment tools and resources.
What Is the Nektar Therapeutics Share Price Today?
The Nektar share price today is 44.4600.
What Is the Stock Symbol for Nektar Therapeutics
The stock symbol (or 'ticker') for Nektar Therapeutics is "NKTR."
What Stock Exchange Does Nektar Therapeutics Trade On?
Nektar Therapeutics is listed and trades on the NASDAQ stock exchange.
Is Nektar Therapeutics a Good Stock to Buy?
Determining whether Nektar Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Nektar Therapeutics share price performance charts on this page. Our technical summary section provides analysis on Nektar share price buy/sell indicators using real-time data (or discuss the Nektar (NKTR) stock price today with other investors in the Nektar NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ NKTR share price (ISIN: US6402683063) to enhance your trading decisions with our free investment tools and resources.
What Is the Nektar Therapeutics Share Price Today?
The Nektar share price today is 44.4600.
What Is the Stock Symbol for Nektar Therapeutics
The stock symbol (or 'ticker') for Nektar Therapeutics is "NKTR."
What Stock Exchange Does Nektar Therapeutics Trade On?
Nektar Therapeutics is listed and trades on the NASDAQ stock exchange.
Is Nektar Therapeutics a Good Stock to Buy?
Determining whether Nektar Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
42.9500
44.5500
52 wk Range
6.4800
66.9200
NKTR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
42.950044.5500
52 wk Range
6.480066.9200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NKTR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
114.4286
Upside
+157.37%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Nektar Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics Earnings Call Summary for Q3/2025
- Nektar reported Q3 2025 net loss of $35.5M ($1.87/share), yet stock rose 1.57% to $54.26; company maintains strong financial position with $270.2M in cash and no debt.
- REZPEG, Nektar's lead program, advances across atopic dermatitis, alopecia areata, and type 1 diabetes therapeutic areas with Phase 3 trials in preparation.
- Company forecasts year-end cash position of approximately $240M, extending runway into Q2 2027; expects top-line alopecia areata data in December 2025.
- Dr. Mary Tagliaferri returns as Chief Medical Officer to strengthen strategic initiatives amid market competition, particularly from JAK inhibitors.
Last Updated: 06/11/2025, 23:44
Read Full TranscriptCompare NKTR to Peers and Sector
Metrics to compare | NKTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNKTRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.5x | −2.8x | −0.6x | |
PEG Ratio | −0.20 | 0.01 | 0.00 | |
Price/Book | 10.6x | 1.6x | 2.6x | |
Price / LTM Sales | 14.4x | 4.5x | 3.2x | |
Upside (Analyst Target) | 158.7% | 96.3% | 41.8% | |
Fair Value Upside | Unlock | 9.3% | 5.1% | Unlock |
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 114.4286
(+157.37% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-1.87 / -0.1928
Revenue / Forecast
11.79M / 9.84M
People Also Watch
FAQ
What Is the Nektar (NKTR) Share Price Today?
The live Nektar share price today is 44.4600
What Stock Exchange Does Nektar (NKTR) Trade On?
Nektar is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Nektar?
The stock symbol (also called a 'ticker') for Nektar is "NKTR."
What Is the Current Nektar Market Cap?
As of today, Nektar market capitalisation is 904.39M.
What Is Nektar's (NKTR) Earnings Per Share (TTM)?
The Nektar EPS is currently -7.90 (Trailing Twelve Months).
Is NKTR a Buy or Sell From a Technical Analyst Perspective?
Based on today's Nektar moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Nektar Stock Split?
Nektar has split 2 times. (See the NKTR stock split history page for full effective split date and price information.)
How Many Employees Does Nektar Have?
Nektar has 61 employees.
What is the current trading status of Nektar (NKTR)?
As of 24 Dec 2025, Nektar (NKTR) is trading at a price of 44.4600, with a previous close of 44.4600. The stock has fluctuated within a day range of 42.9500 to 44.5500, while its 52-week range spans from 6.4800 to 66.9200.
What Is Nektar (NKTR) Price Target According to Analysts?
The average 12-month price target for Nektar is USD114.42857, with a high estimate of USD135 and a low estimate of USD102. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +157.37% Upside potential.
What Is the NKTR After Hours Price?
NKTR's last after hours stock price is 43.9900, the stock has decreased by -0.4700, or -1.0600%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.